Nykode Therapeutics (Buy, TP: NOK31.00) - Q2 report and C-04 discontinuation
The company announced it has decided to discontinue the C-04 trial based on standard-of-care changes and feedback from key opinion leaders. Regarding the recently announced Genentech reorganisation, it said that it has “not received any indications of the partnership being affected”.Vaccibody AS. Vaccibody AS is a Norway-based vaccine company. It is engaged in the development of vaccines that overcome the shortcomings of current vaccine technologies. The Company's vaccine platform increases the antibody and T-cell responses. The Company focuses on cancer vaccines, partnering the technology within infection and veterinary use. The Company develops of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer. The major shareholders of the Company are BMI, Sarsia Seed and the investors.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.